



**Supplementary Fig. 5.** Follow-up of patients in remission group for 1 year after initial trough levels of infliximab (TLI) measurements. Patients in the remission group were separated into antibodies to infliximab (ATI)-positive (ATI >4.9  $\mu\text{g}/\text{mL}$ ) and ATI-negative (ATI  $\leq$ 4.9  $\mu\text{g}/\text{mL}$ ) groups. The rates of infusion reaction were 17.6% in the ATI-positive group and 2.9% in the ATI-negative group ( $P=0.0967$ ), and the loss of response (LOR) rates after 1 year were 6.7% and 2.9%, respectively ( $P=0.5230$ ), while the proportions in whom TLI had decreased by  $\geq$ 50.0% were 7.7% and 0%, respectively ( $P=1.0000$ ).